ISIS 2302 antisense inhibitor of ICAM-1 cell adhesion protein: Began Phase II trials in five diseases, with 20 to 40 patients in each study. Results should be a

Isis Pharmaceuticals Inc. (ISIP), Carlsbad, Calif. Product: ISIS 2302 antisense inhibitor of ICAM-1 cell adhesion protein, which guides inflammatory cells out of the bloodstream to tissues Indicatio...